{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:37:02Z","timestamp":1793363822880,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-026-10401-5","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:36:51Z","timestamp":1774946211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ductal adenocarcinoma following gemcitabine-based therapy. A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"43","author":[{"given":"Elsa","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Maistrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Monica","family":"Sciacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Fanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Massafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lotesoriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Gadaleta-Caldarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oronzo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"3","key":"10401_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12029-015-9724-1","volume":"46","author":"A Carrato","year":"2015","unstructured":"Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C, Parthenaki I (2015) A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. J Gastrointest Cancer 46(3):201\u2013211. https:\/\/doi.org\/10.1007\/s12029-015-9724-1","journal-title":"J Gastrointest Cancer"},{"key":"10401_CR2","doi-asserted-by":"publisher","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. ;74(11):2913-21. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155. Erratum in: Cancer Res. 2014;74(14):4006","DOI":"10.1158\/0008-5472.CAN-14-0155"},{"key":"10401_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: An overview. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.33588","journal-title":"Int J Cancer"},{"issue":"3","key":"10401_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, L\u00f3pez-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P (2020) Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5(3):285\u2013294. https:\/\/doi.org\/10.1016\/S2468-1253(19)30327-9","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10401_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2468-1253(17)30046-8","volume":"2","author":"JB Bachet","year":"2017","unstructured":"Bachet JB, Hammel P, Desram\u00e9 J, Meurisse A, Chibaudel B, Andr\u00e9 T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C (2017) Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Lancet Gastroenterol Hepatol 2(5):337\u2013346. https:\/\/doi.org\/10.1016\/S2468-1253(17)30046-8","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10401_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","volume":"6","author":"V Kunzmann","year":"2021","unstructured":"Kunzmann V, Siveke JT, Alg\u00fcl H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V, German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators (2021) Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 6(2):128\u2013138. https:\/\/doi.org\/10.1016\/S2468-1253(20)30330-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl4","key":"10401_CR7","doi-asserted-by":"publisher","first-page":"iv157","DOI":"10.1093\/annonc\/mdx244","volume":"28","author":"ESMO Guidelines Committee","year":"2017","unstructured":"ESMO Guidelines Committee (2017) Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org\/Guidelines\/Gastrointestinal-Cancers). Ann Oncol 28(suppl4):iv157. https:\/\/doi.org\/10.1093\/annonc\/mdx244","journal-title":"Ann Oncol"},{"issue":"19","key":"10401_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardi\u00e8re C, Bennouna J, Bachet JB, Khemissa-Akouz F, P\u00e9r\u00e9-Verg\u00e9 D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"2","key":"10401_CR9","doi-asserted-by":"publisher","first-page":"e220022","DOI":"10.1148\/rycan.220022","volume":"5","author":"H Ravi","year":"2023","unstructured":"Ravi H, Arias-Lorza AM, Costello JR, Han HS, Jeong DK, Klinz SG, Sachdev JC, Korn RL, Raghunand N (2023) Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer. Radiol Imaging Cancer 5(2):e220022. https:\/\/doi.org\/10.1148\/rycan.220022","journal-title":"Radiol Imaging Cancer"},{"issue":"10","key":"10401_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/CAD.0000000000000545","volume":"28","author":"SC Leonard","year":"2017","unstructured":"Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS (2017) Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs 28(10):1086\u20131096. https:\/\/doi.org\/10.1097\/CAD.0000000000000545","journal-title":"Anticancer Drugs"},{"issue":"23","key":"10401_CR11","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","volume":"74","author":"AV Kalra","year":"2014","unstructured":"Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, Nielsen UB, Fitzgerald JB (2014) Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res 74(23):7003\u20137013. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0572","journal-title":"Cancer Res"},{"issue":"2","key":"10401_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/cas.14264","volume":"111","author":"YJ Bang","year":"2020","unstructured":"Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, Chen LT (2020) Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Cancer Sci 111(2):513\u2013527. https:\/\/doi.org\/10.1111\/cas.14264","journal-title":"Cancer Sci"},{"key":"10401_CR13","doi-asserted-by":"publisher","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT, NAPOLI-1 Study Group (2016). Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. ;387(10018):545\u2013557. doi: 10.1016\/S0140-6736(15)00986-1. Erratum in: Lancet. 2016;387(10018):536. https:\/\/doi.org\/10.1016\/S0140-6736(15)01306-9","DOI":"10.1016\/S0140-6736(15)01306-9"},{"issue":"1","key":"10401_CR14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1186\/s12885-016-2933-6","volume":"16","author":"NJ Chiang","year":"2016","unstructured":"Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang YW, Yeh CG, Chen LT (2016) A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer 16(1):907. https:\/\/doi.org\/10.1186\/s12885-016-2933-6","journal-title":"BMC Cancer"},{"issue":"5","key":"10401_CR15","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-14-1882","volume":"21","author":"MH Kang","year":"2015","unstructured":"Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP (2015) Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing\u2019s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res 21(5):1139\u20131150. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1882","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10401_CR16","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","volume":"24","author":"AC Roy","year":"2013","unstructured":"Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A (2013) A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 24(6):1567\u20131573. https:\/\/doi.org\/10.1093\/annonc\/mdt002","journal-title":"Ann Oncol"},{"issue":"1","key":"10401_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jcm7010007","volume":"7","author":"S Thibodeau","year":"2018","unstructured":"Thibodeau S, Voutsadakis IA (2018) FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies. J Clin Med 7(1):7. https:\/\/doi.org\/10.3390\/jcm7010007","journal-title":"J Clin Med"},{"key":"10401_CR18","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. ;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898. PMID: 31462531","DOI":"10.1136\/bmj.l4898"},{"issue":"1","key":"10401_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/bimj.201900036","volume":"62","author":"S McGrath","year":"2020","unstructured":"McGrath S, Sohn H, Steele R, Benedetti A (2020) Meta-analysis of the difference of medians. Biom J 62(1):69\u201398","journal-title":"Biom J"},{"issue":"7300","key":"10401_CR20","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/bmj.322.7300.1479","volume":"322","author":"S Lewis","year":"2001","unstructured":"Lewis S, Clarke M (2001) Forest plots: trying to see the wood and the trees. BMJ 322(7300):1479\u20131480. https:\/\/doi.org\/10.1136\/bmj.322.7300.1479","journal-title":"BMJ"},{"key":"10401_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2018.09.010","volume":"105","author":"LT Chen","year":"2018","unstructured":"Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA (2018) Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. Eur J Cancer 105:71\u201378. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10401_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-024-01948-4","volume":"9","author":"J Cui","year":"2024","unstructured":"Cui J, Qin S, Zhou Y, Zhang S, Sun X, Zhang M, Cui J, Fang W, Gu K, Li Z, Wang J, Chen X, Yao J, Zhou J, Wang G, Bai Y, Xiao J, Qiu W, Wang B, Xia T, Wang C, Kong L, Yin J, Zhang T, Shen X, Fu D, Gao C, Wang H, Wang Q, Wang L (2024) Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. Signal Transduct Target Ther 9(1):248. https:\/\/doi.org\/10.1038\/s41392-024-01948-4","journal-title":"Signal Transduct Target Ther"},{"issue":"24","key":"10401_CR23","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1002\/cam4.3558","volume":"9","author":"M Ueno","year":"2020","unstructured":"Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Tang R, Ioka T (2020) nal-IRI\u2009+\u20095-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med 9(24):9396\u20139408. https:\/\/doi.org\/10.1002\/cam4.3558","journal-title":"Cancer Med"},{"key":"10401_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT (2019) NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 108:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.007","journal-title":"Eur J Cancer"},{"key":"10401_CR25","unstructured":"Cochrane Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. Availability from: https:\/\/www.cochrane.org Accessed on 21.06.2025"},{"issue":"1","key":"10401_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13643-021-01824-0","volume":"10","author":"TC Hirst","year":"2021","unstructured":"Hirst TC, Sena ES, Macleod MR (2021) Using median survival in meta-analysis of experimental time-to-event data. Syst Rev 10(1):292. https:\/\/doi.org\/10.1186\/s13643-021-01824-0","journal-title":"Syst Rev"},{"issue":"4","key":"10401_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10637-024-01442-2","volume":"42","author":"D Ji","year":"2024","unstructured":"Ji D, Shen W, Li T, Wang H, Bai J, Cao J, Hu X (2024) Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study. Invest New Drugs 42(4):462\u2013470. https:\/\/doi.org\/10.1007\/s10637-024-01442-2","journal-title":"Invest New Drugs"},{"issue":"8","key":"10401_CR28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","volume":"9","author":"A Vogel","year":"2024","unstructured":"Vogel A, Saborowski A, Wenzel P, Wege H, Folprecht G, Kretzschmar A, Sch\u00fctt P, Jacobasch L, Ziegenhagen N, Boeck S, Zhang D, Kanzler S, Belle S, Mohm J, G\u00f6kkurt E, Lerchenm\u00fcller C, Graeven U, Pink D, G\u00f6tze T, Kirstein MM (2024) Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 9(8):734\u2013744. https:\/\/doi.org\/10.1016\/S2468-1253(24)00119-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10401_CR29","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/bjc.2013.408","volume":"109","author":"AH Ko","year":"2013","unstructured":"Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT (2013) A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 109(4):920\u2013925. https:\/\/doi.org\/10.1038\/bjc.2013.408","journal-title":"Br J Cancer"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10401-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:36:55Z","timestamp":1774946215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-026-10401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["10401"],"URL":"https:\/\/doi.org\/10.1007\/s10585-026-10401-5","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The authors affiliated to the IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Bari are responsible for the views expressed in this article, which do not necessarily represent the Institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"21"}}